The Effect of Aprotinin on Outcome after Coronary-Artery Bypass Grafting
Authors:
- Andrew D. ShawASAndrew D. Shaw
- Mark Stafford-SmithMSMark Stafford-Smith
- William D. WhiteWWWilliam D. White
- Barbara Phillips-ButeBPBarbara Phillips-Bute
- Madhav SwaminathanMSMadhav Swaminathan
- Carmelo MilanoCMCarmelo Milano
- Ian J. WelsbyIWIan J. Welsby
- Solomon AronsonSASolomon Aronson
- Joseph P. MathewJMJoseph P. Mathew
- Eric D. PetersonEPEric D. Peterson
- Mark F. NewmanMNMark F. Newman
Open Access
- 21 February 2008
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (8) , 784-793
Abstract
Aprotinin has recently been associated with adverse outcomes in patients undergoing cardiac surgery. We reviewed our experience with this agent in patients undergoing cardiac surgery at Duke University Medical Center. We retrieved data on 10,275 consecutive patients undergoing surgical coronary revascularization at Duke between January 1, 1996, and December 31, 2005. We fit data to a logistic-regression model predicting each patient's likelihood of receiving aprotinin on the basis of preoperative characteristics and to models predicting long-term survival (up to 10 years) and decline in renal function, as measured by increases in serum creatinine levels. A total of 1343 patients (13.2%) received aprotinin, 6776 patients (66.8%) received aminocaproic acid, and 2029 patients (20.0%) received no antifibrinolytic therapy. All patients underwent coronary-artery bypass grafting, and 1181 patients (11.5%) underwent combined coronary-artery bypass grafting and valve surgery. In the risk-adjusted model, survival was worse among patients treated with aprotinin, with a main-effects hazard ratio for death of 1.32 (95% confidence interval [CI], 1.12 to 1.55) for the comparison with patients receiving no antifibrinolytic therapy (P=0.003) and 1.27 (95% CI, 1.10 to 1.46) for the comparison with patients receiving aminocaproic acid (P=0.004). As compared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associated with a larger risk-adjusted increase in the serum creatinine level (P<0.001) but not with a greater risk-adjusted incidence of dialysis (P=0.56). Patients who received aprotinin had a higher mortality rate and larger increases in serum creatinine levels than those who received aminocaproic acid or no antifibrinolytic agent.Keywords
This publication has 14 references indexed in Scilit:
- Aprotinin and Anaphylaxis: Analysis of 12,403 Exposures to Aprotinin in Cardiac SurgeryThe Annals of Thoracic Surgery, 2007
- Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome?British Journal of Anaesthesia, 2007
- Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac SurgeryCirculation, 2007
- Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft SurgeryJAMA, 2007
- Is There Still a Role for Aprotinin in Cardiac Surgery?Drug Safety, 2007
- The Risk Associated with Aprotinin in Cardiac SurgeryNew England Journal of Medicine, 2006
- A propensity score case‐control comparison of aprotinin and tranexamic acid in high‐transfusion‐risk cardiac surgeryTransfusion, 2006
- Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgeryThe Annals of Thoracic Surgery, 2002
- Variability in Transfusion Practice for Coronary Artery Bypass Surgery Persists Despite National Consensus GuidelinesAnesthesiology, 1998
- EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERYThe Lancet, 1987